UCB : acquires Lectus Therapeutics'' key pharmaceutical assets
UCB has acquired Lectus Therapeutics's key pharmaceutical assets today via a licence and acquisition agreement.
Provectus Pharmaceuticals, a biotech company developing oncology and dermatology drugs, has inked a $1 million investment from Chicago-based Lincoln Park Capital Fund.